FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288062007> ?p ?o ?g. }

• W4288062007 endingPage "1" @default.
• W4288062007 startingPage "1" @default.
• W4288062007 abstract "Objective: Macrophage activation syndrome (MAS) develops due to increased expression of systemic pro-inflammatory cytokines in patients with the 2019 novel coronavirus disease (COVID-19). Immune modulators have been used in anti-cytokine therapy, with the hypothesis that they can ensure cytokine inhibition and treat cytokine storm. The present study aimed to evaluate inflammatory and prognostic biomarkers in severe COVID-19 cases treated with tocilizumab (TCZ) alone or with the combination of tocilizumab and convalescent plasma transfusion (CPT). Materials and Methods: In this retrospective study, data archives of patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) and who were treated with TCZ alone or the combination of CPT and TCZ were evaluated in line with the literature. The obtained data were statistically evaluated and the alpha significance value was taken as <0.05. Results: Post-treatment C-reactive protein (CRP) (76.19% in TCZ-administered group; 89.32% in TCZ+CPT-administered group) (P<0.05), troponin I (TNI) (25.64% in TCZ-administered group; 90.39% in TCZ+CPT-administered group) (P<0.05), and ferritin (FER) (63.63% in the TCZ-administered group; 9.09% in the TCZ+CPT-administered) (P<0.05) levels were decreased compared to pre-treatment stage. The mean length of hospital stay was longer in the patients treated with TCZ alone (21.55±8.89 days) than in the patients treated with the combination of TCZ and CPT (27.09±13.66 days) (P<0.05). Conclusion: There was no significant difference between the groups in terms of demographic characteristics. The combination of TCZ and CPT treatment did not decrease the mortality. A significant decrease in CRP and TNI levels was observed in the patients treated with TCZ alone and with the combination of TCZ and CPT. A decrease in FER levels showed the effectiveness of the treatments." @default.
• W4288062007 created "2022-07-28" @default.
• W4288062007 creator A5011536847 @default.
• W4288062007 creator A5018899240 @default.
• W4288062007 creator A5063272576 @default.
• W4288062007 creator A5075119549 @default.
• W4288062007 creator A5083796860 @default.
• W4288062007 date "2022-01-01" @default.
• W4288062007 modified "2023-10-17" @default.
• W4288062007 title "Evaluation of inflammatory and biochemical markers in COVID-19 patients treated with tocilizumab alone or with the combination of tocilizumab and convalescent plasma transfusion" @default.
• W4288062007 doi "https://doi.org/10.5455/annalsmedres.2022.02.048" @default.
• W4288062007 hasPublicationYear "2022" @default.
• W4288062007 type Work @default.
• W4288062007 citedByCount "0" @default.
• W4288062007 crossrefType "journal-article" @default.
• W4288062007 hasAuthorship W4288062007A5011536847 @default.
• W4288062007 hasAuthorship W4288062007A5018899240 @default.
• W4288062007 hasAuthorship W4288062007A5063272576 @default.
• W4288062007 hasAuthorship W4288062007A5075119549 @default.
• W4288062007 hasAuthorship W4288062007A5083796860 @default.
• W4288062007 hasBestOaLocation W42880620071 @default.
• W4288062007 hasConcept C11988809 @default.
• W4288062007 hasConcept C126322002 @default.
• W4288062007 hasConcept C2777178219 @default.
• W4288062007 hasConcept C2778319317 @default.
• W4288062007 hasConcept C2778690821 @default.
• W4288062007 hasConcept C2779134260 @default.
• W4288062007 hasConcept C2779559532 @default.
• W4288062007 hasConcept C3008058167 @default.
• W4288062007 hasConcept C524204448 @default.
• W4288062007 hasConcept C71924100 @default.
• W4288062007 hasConcept C90924648 @default.
• W4288062007 hasConceptScore W4288062007C11988809 @default.
• W4288062007 hasConceptScore W4288062007C126322002 @default.
• W4288062007 hasConceptScore W4288062007C2777178219 @default.
• W4288062007 hasConceptScore W4288062007C2778319317 @default.
• W4288062007 hasConceptScore W4288062007C2778690821 @default.
• W4288062007 hasConceptScore W4288062007C2779134260 @default.
• W4288062007 hasConceptScore W4288062007C2779559532 @default.
• W4288062007 hasConceptScore W4288062007C3008058167 @default.
• W4288062007 hasConceptScore W4288062007C524204448 @default.
• W4288062007 hasConceptScore W4288062007C71924100 @default.
• W4288062007 hasConceptScore W4288062007C90924648 @default.
• W4288062007 hasIssue "7" @default.
• W4288062007 hasLocation W42880620071 @default.
• W4288062007 hasOpenAccess W4288062007 @default.
• W4288062007 hasPrimaryLocation W42880620071 @default.
• W4288062007 hasRelatedWork W3021795503 @default.
• W4288062007 hasRelatedWork W3026277345 @default.
• W4288062007 hasRelatedWork W3092879025 @default.
• W4288062007 hasRelatedWork W3100813037 @default.
• W4288062007 hasRelatedWork W3132427123 @default.
• W4288062007 hasRelatedWork W3168330114 @default.
• W4288062007 hasRelatedWork W4205993479 @default.
• W4288062007 hasRelatedWork W4285795734 @default.
• W4288062007 hasRelatedWork W4289262226 @default.
• W4288062007 hasRelatedWork W4206851384 @default.
• W4288062007 hasVolume "29" @default.
• W4288062007 isParatext "false" @default.
• W4288062007 isRetracted "false" @default.
• W4288062007 workType "article" @default.